- An analyst from Jefferies recently raised the price target for Roivant Sciences to $52, suggesting a potential upside of 24.7%.
- Pulmovant, a Roivant company, announced strong Phase 2 clinical trial results for mosliciguat, showing a significant 56.3% reduction in pulmonary vascular resistance (PVR) for PH-ILD.
- Further positive developments, including a recent FDA approval for LISRAYA, support the higher valuation for the biopharmaceutical company.
Roivant Sciences (NASDAQ:ROIV) is a biopharmaceutical company that focuses on developing medicines and technologies. It operates through subsidiary companies, known as “Vants,” each dedicated to a specific area of drug development. This model allows Roivant Sciences to pursue multiple therapies across different diseases at the same time.
An analyst from Jefferies recently increased the price target for Roivant Sciences to $52. This update reflects growing confidence in the company’s drug pipeline. The new target was set when the stock was trading at $41.70, suggesting a potential increase of about 24.7% for investors.
This positive outlook is driven by strong clinical trial results. Pulmovant, a Roivant company, announced that its Phase 2 study for mosliciguat met its main goal. The drug is being tested for pulmonary hypertension associated with interstitial lung disease (PH-ILD), a serious lung condition with limited treatment options.
The study showed a significant, placebo-adjusted reduction in pulmonary vascular resistance (PVR) of 56.3%. PVR measures the resistance blood must overcome to flow through the lungs. This result is the highest PVR reduction ever seen in a similar controlled trial. As highlighted by Reuters, this news caused Roivant Sciences shares to climb approximately 20% in premarket trading.
Further data showed improvements in how far patients could walk in six minutes and reductions in a key heart stress indicator. The positive developments also include a recent FDA approval for LISRAYA, a new therapy for a rare skin and muscle disease. These successful outcomes support the analyst’s higher valuation for the company.
